Recent Updates
Recently added Catalysts

AF-130

Phase 1

Healthy Volunteers | Small molecule | Other |Merck & Company, Inc.|Last Updated: Dec 6, 2016

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment80
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02652936A Pharmacokinetics Study of AF-130 in Healthy SubjectsPHASE1 COMPLETED 80Oct 1, 2015Mar 1, 2016Dec 6, 20161 United Kingdom
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of subjects with treatment-related adverse events following a single oral dose of AF-130
48 hours
Number of subjects with treatment-related adverse events following multiple oral doses of AF-130
7 days
Secondary Endpoints
Maximum plasma concentration (Cmax) profile of an oral formulation of AF-130
48 hours
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
AF-130 capsuleEXPERIMENTALAF-130 oral capsules administered as a single dose or once daily for 7 days
AF-130 matching placebo capsulePLACEBO_COMPARATOROral placebo capsules to match AF-130 administered as a single dose or once daily for 7 days
Interventions
NameTypeDescription
AF-130DRUGAF-130 oral capsules (50 mg) administered as a single dose or once daily for 7 days
Placebo comparatorDRUGAF-130 matching placebo capsule
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 55 Years
SexMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Healthy males * Age 18 to 55 years * Body mass index of 18.0 to 35.0 kg/m2 * Willing and able to communicate and participate in the whole study * Must provide written informed consent * Must agree to use an adequate method of contraception Exclusion Criteria: * Participation...

Countries:United Kingdom
Unlock Eligibility Criteria